Monoclonal Antibodies (mAbs) Products for Immunotherapy Treatment
J.T.Baker® BAKERBOND™ PROchievA™ protein A chromatography resinsImprove your efficiency with high-performance protein A chromatography resins for mAbs production processes. Learn moremAbs WorkflowFrom discovery to delivery, you can trust Avantor® to provide the mAbs products and tools you need to streamline your workflow and improve your processes. We carry thousands of antibodies, high-yield antibody purification buffers, and immunotherapeutic support to help you drive discovery. Ready to Get Started?Ready to Maximize Production Efficiency? Our Bioprocessing Solutions team can help you streamline your biomanufacturing processes! Get StartedPUPSIT: Exceeding expectations is the standard, not the exceptionAvantor uses PUPSIT globally to reduce filter defects and contamination. We go beyond compliance in every detail, every day. What Are Monoclonal Antibodies?Monoclonal antibodies, also called mAbs, are proteins made in a laboratory that act identically to immune system antibodies. These manufactured antibodies come from a single unique parent cell and are exact replicas of antibodies that target one specific antigen. That makes them ideal for targeted monoclonal antibodies immunotherapy. Among the uses for monoclonal antibodies are the treatment diseases, including:
Monoclonal antibodies are used for a variety of diagnostic procedures that include:
How Do Monoclonal Antibodies Work?Monoclonal antibodies (mAbs) work in a variety of ways depending on the protein they are targeting. Each mAb mimics one of the body’s natural antibodies and functions as immunotherapy by targeting one particular protein to:
Future of Monoclonal Antibodies TreatmentMonoclonal antibodies (mAbs) are the largest sector in the biologics market, based on revenues and drug pipelines. The clinical benefit of mAbs has been effective in treating autoimmune diseases and oncology. Significant investments are now focusing on developing mAbs for the growing field of immuno-oncology or monoclonal antibodies immunotherapy. Efforts include process optimization to increase mAb titers, mAb fragments manufactured in other expression systems, multiple target specificity for mAbs, and the development of Antibody-Drug Conjugates (ADCs) that deliver highly toxic drugs to targeted cancer cells. |